Paper28693199
Epidermal growth factor receptor in glioblastoma.
Xu H and 8 others. Oncol Lett, 2017. Cited by 123 papers, by iCite.
Cite this record
ConductScience Library. Epidermal growth factor receptor in glioblastoma. Papers, record 28693199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28693199
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20124186 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20124186 | PubMed |
| 2 | 21775422 | Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity. | Mol Cancer Res | 2011 | https://conductscience.org/library/papers/21775422 | PubMed |
| 3 | 19499221 | A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. | Cancer Chemother Pharmacol | 2010 | https://conductscience.org/library/papers/19499221 | PubMed |
| 4 | 12734385 | Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12734385 | PubMed |
| 5 | 14583498 | Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. | Cancer Res | 2003 | https://conductscience.org/library/papers/14583498 | PubMed |
| 6 | 7531822 | Protein modules and signalling networks. | Nature | 1995 | https://conductscience.org/library/papers/7531822 | PubMed |
| 7 | 19738203 | Oncogenic EGFR signaling networks in glioma. | Sci Signal | 2009 | https://conductscience.org/library/papers/19738203 | PubMed |
| 8 | 11302336 | Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. | Neuro Oncol | 2000 | https://conductscience.org/library/papers/11302336 | PubMed |
| 9 | 20150372 | A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20150372 | PubMed |
| 10 | 17177598 | Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. | PLoS Med | 2006 | https://conductscience.org/library/papers/17177598 | PubMed |
| 11 | 17970081 | Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. | Anticancer Res | 2007 | https://conductscience.org/library/papers/17970081 | PubMed |
| 12 | 7518560 | Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. | Mol Cell Biol | 1994 | https://conductscience.org/library/papers/7518560 | PubMed |
| 13 | 20562912 | Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. | Oncogene | 2010 | https://conductscience.org/library/papers/20562912 | PubMed |
| 14 | 8695267 | Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. | Eur J Cancer | 1996 | https://conductscience.org/library/papers/8695267 | PubMed |
| 15 | 24212795 | Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. | Cancers (Basel) | 2011 | https://conductscience.org/library/papers/24212795 | PubMed |
| 16 | 16728632 | Targeting tyrosine kinases in cancer: the second wave. | Science | 2006 | https://conductscience.org/library/papers/16728632 | PubMed |
| 17 | 15136790 | Development of novel targeted therapies in the treatment of malignant glioma. | Nat Rev Drug Discov | 2004 | https://conductscience.org/library/papers/15136790 | PubMed |
| 18 | 19204207 | Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19204207 | PubMed |
| 19 | 20085938 | The PI3K pathway as drug target in human cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20085938 | PubMed |
| 20 | 8052651 | A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. | Proc Natl Acad Sci U S A | 1994 | https://conductscience.org/library/papers/8052651 | PubMed |
Cited by85
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42694163 | Niemann-Pick type C1 protein regulates epidermal growth factor receptor stability in hepatic cells and facilitates the early steps of Hepatitis B virus infection. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42694163 | PubMed |
| 42683315 | The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42683315 | PubMed |
| 42589248 | Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589248 | PubMed |
| 42566443 | A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor. | PLoS One | 2026 | https://conductscience.org/library/papers/42566443 | PubMed |
| 42549406 | Targeting replication stress in glioblastoma: From genotoxic treatment and inhibitors of the DNA damage response to immunotherapy. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42549406 | PubMed |
| 42279368 | Mitochondrial Metabolic Reprogramming in Colorectal Cancer-Associated Fibroblasts: An Up-to-Date Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279368 | PubMed |
| 42269611 | Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer. | Cell Chem Biol | 2026 | https://conductscience.org/library/papers/42269611 | PubMed |
| 41783089 | Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/41783089 | PubMed |
| 41497449 | Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma. | Neurooncol Adv | 2025 | https://conductscience.org/library/papers/41497449 | PubMed |
| 41493642 | An in silico approach to peptide-based dual-receptor targeting for IL13RA2 and VEGFR-2 extracellular domain. | J Mol Model | 2026 | https://conductscience.org/library/papers/41493642 | PubMed |
| 41473440 | A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model. | Front Oncol | 2025 | https://conductscience.org/library/papers/41473440 | PubMed |
| 41208963 | Emerging insights into the immunosuppressive tumor microenvironment and its implications for glioblastoma immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41208963 | PubMed |
| 41034696 | Characterisation of the expression of P2X7 receptor, cancer stem cell markers and immunological mediators in human high-grade gliomas. | BMC Neurosci | 2025 | https://conductscience.org/library/papers/41034696 | PubMed |
| 40781177 | Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment. | Med Oncol | 2025 | https://conductscience.org/library/papers/40781177 | PubMed |
| 40722784 | Sex-Related Differences in Glioblastoma: A Single-Center Retrospective Cohort Study. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722784 | PubMed |
| 40540177 | A New Insight in Cellular and Molecular Signaling Regulation for Neural Differentiation Program. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/40540177 | PubMed |
| 40241139 | Application of EGFR-TKIs in brain tumors, a breakthrough in future? | J Transl Med | 2025 | https://conductscience.org/library/papers/40241139 | PubMed |
| 39772250 | Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection. | Viruses | 2024 | https://conductscience.org/library/papers/39772250 | PubMed |
| 39607670 | Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma. | Pharmacol Rep | 2025 | https://conductscience.org/library/papers/39607670 | PubMed |
| 39518074 | Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39518074 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28693199
GET https://conductscience.org/api/papers/v1/28693199/references?page=2